摘要
目的探讨老年冠心病合并高脂血症患者采取瑞舒伐他汀钙进行治疗的临床疗效。方法80例老年冠心病合并高脂血症患者,通过电脑随机法分为对照组和研究组,每组40例。两组患者均接受临床基础治疗,在此基础上,对照组患者采用阿托伐他汀治疗,研究组患者采用瑞舒伐他汀钙治疗。比较两组患者治疗前后血脂指标(总胆固醇、甘油三酯、低密度脂蛋白胆固醇以及高密度脂蛋白胆固醇)水平,临床疗效,不良反应发生情况。结果治疗前,两组患者的总胆固醇、甘油三酯、低密度脂蛋白胆固醇以及高密度脂蛋白胆固醇水平比较差异无统计学意义(P>0.05);治疗后,研究组患者的总胆固醇(1.20±0.29)mmol/L、甘油三酯(4.30±0.38)mmol/L以及低密度脂蛋白胆固醇(4.00±0.56)mmol/L均显著低于对照组的(1.72±0.38)、(5.08±0.48)、(5.13±0.58)mmol/L,高密度脂蛋白胆固醇(1.44±0.19)mmol/L显著高于对照组的(1.10±0.32)mmol/L,差异具有统计学意义(P<0.05)。研究组患者的治疗总有效率为90.0%,显著高于的对照组的60.0%,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论老年冠心病合并高脂血症患者采用瑞舒伐他汀钙进行治疗的临床疗效明显,能够有效改善患者的血脂水平,治疗安全性高,应该给予大力的推广与应用。
Objective To discuss the clinical efficacy of rosuvastatin calcium on coronary artery disease combined with hyperlipidemia in the elderly.Methods A total of 80 elderly patients with coronary heart disease and hyperlipidemia were divided into a control group and a research group by computerized randomization method,with 40 patients in each group.Patients in both groups received clinical basic treatment.On this basis,patients in the control group were treated with atorvastatin,and patients in the research group were treated with resulvastatin calcium.The levels of blood lipid indexes(total cholesterol,triglycerides,low density lipoprotein cholesterol and high density lipoprotein cholesterol cholesterol)before and after treatment,clinical efficacy,and the occurrence of adverse reactions were compared between the two groups.Results Before treatment,there was no statistically significant difference in the levels of total cholesterol,triglycerides,low density lipoprotein cholesterol and high density lipoprotein cholesterol cholesterol between the two groups(P>0.05).After treatment,the total cholesterol(1.20±0.29)mmol/L,triglycerides(4.30±0.38)mmol/L and low density lipoprotein cholesterol(4.00±0.56)mmol/L in the research group were significantly lower than(1.72±0.38),(5.08±0.48),(5.13±0.58)mmol/L in the control group;the high density lipoprotein cholesterol(1.44±0.19)mmol/L in the research group was significantly higher than(1.10±0.32)mmol/L in the control group;the differences were statistically significant(P<0.05).The total effective rate of treatment in the research group was 90.0%,which was significantly higher than 60.0%in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The clinical efficacy of rosuvastatin calcium in the treatment of elderly patients with coronary heart disease and hyperlipidemia is obvious,which can effectively improve the blood lipi
作者
栗明
LI Ming(Department of Internal Medicine,Huanren Manchu Autonomous County Hospital of Traditional Chinese Medicine,Benxi 117200,China)
出处
《中国现代药物应用》
2023年第2期111-113,共3页
Chinese Journal of Modern Drug Application
关键词
老年冠心病
高脂血症
瑞舒伐他汀钙
血脂指标
不良反应
Coronary artery disease in the elderly
Hyperlipidemia
Rosuvastatin calcium
Blood lipid index
Adverse reactions
